If UnitedHealth Group’s (NYSE: UNH) stock price implosion was driven by margin, earnings, and capital return concerns, the Q3 results put them to rest.
While the business reflects margin impacts, top and bottom-line results are better than expected, revealing growth, momentum, and a favorable outlook that underpin the capital return quality. In this environment, the stock is a deep value, trading at less than 10x its 2030 earnings forecasts, which are likely to be low.
